BioTechne (TECH) Fell Over the Industry’s Uncertain Funding Environment

Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The quarter started with tariff uncertainty, conflicts in the Middle East, rising national debt, and the worst start to a year for the dollar; however, it bounced back to rise 25% from that low by the end of the quarter. The fund returned 2.66% in the first half of 2025. The fund underperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), which were up 5.43% and the Morningstar Moderate Allocation peer group, which rose 5.67%. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, Mairs & Power Balanced Fund highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $8.239 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -5.87%, and its shares lost 29.39% of their value over the last 52 weeks. On September 23, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $52.92 per share.

Mairs & Power Balanced Fund stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its second quarter 2025 investor letter:

“Bio-Techne Corporation (NASDAQ:TECH), which makes high quality ingredients for biopharmaceutical research and production, underperformed due to uncertainty around the industry’s funding environment given recent federal funding cuts and a weak venture capital funding environment. We have taken advantage of the recent weakness to add to our Bio-Techne holdings.”

Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 37 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the second quarter, compared to 34 in the previous quarter. In the fiscal fourth quarter of 2025, Bio-Techne Corporation (NASDAQ:TECH) generated $317 million in revenues, up 3% year-over-year on an organic basis and 4% on reported basis.  While we acknowledge the risk and potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Bio-Techne Corporation (NASDAQ:TECH) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared The Brown Capital Management Small Company Fund’s views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.